为什么用羟氯喹进行暴露前预防是一种安全且合理的针对 SARS-CoV-2 感染的方法？
Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
机构信息
Department of Medicine, SMS Medical College, Jaipur, India.
Department of Medicine, SMS Medical College, Jaipur, India.
出版信息
J Glob Antimicrob Resist. 2020 Sep;22:864-865. doi: 10.1016/j.jgar.2020.07.022. Epub 2020 Aug 7.
Abstract
The potentiality of Hydroxychloroquine (HCQ) for pre-exposure prophylaxis against SARS-CoV-2 has not been explored in randomized controlled trials. However, there is rationale behind this potentiality in terms of demonstrated in-vitro effect of HCQ against SARS-CoV-2, safety profile of HCQ in healthy individuals and a recent observational study demonstrating benefits of HCQ prophylaxis in terms of a significant reduction (>80%) in the odds of SARS-CoV-2 infection in the health-care workers (HCWs) with the intake of six or more doses of HCQ prophylaxis as per the guidelines of the National Task Force for COVID-19 in India. Hence, pre-exposure prophylaxis with HCQ in appears to be a reasonable strategy in the current scenario for prevention of SARS-CoV-2 infection in healthy HCWs.
摘要
羟氯喹（HCQ）预防 SARS-CoV-2 的潜力尚未在随机对照试验中得到探索。然而，HCQ 具有以下潜在作用：已证明 HCQ 在体外对 SARS-CoV-2 具有抑制作用、HCQ 在健康个体中的安全性特征，以及最近的一项观察性研究表明，HCQ 预防可带来益处，可显著降低（>80%）根据印度国家 COVID-19 工作队的指南，接受 6 剂或更多 HCQ 预防剂量的医护人员（HCWs）感染 SARS-CoV-2 的几率。因此，在当前情况下，HCQ 暴露前预防对于预防健康 HCWs 感染 SARS-CoV-2 似乎是一种合理的策略。
相似文献
1
Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?为什么用羟氯喹进行暴露前预防是一种安全且合理的针对 SARS-CoV-2 感染的方法？
J Glob Antimicrob Resist. 2020 Sep;22:864-865. doi: 10.1016/j.jgar.2020.07.022. Epub 2020 Aug 7.
2
Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.羟氯喹预防 SARS-CoV-2 感染和妊娠期 COVID-19 疾病严重程度的疗效和安全性（COVID-Preg）：一项随机安慰剂对照试验研究方案的结构化总结。
Trials. 2020 Jul 2;21(1):607. doi: 10.1186/s13063-020-04557-y.
3
Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.羟氯喹用于接触新冠病毒疾病（COVID-19）后成年人暴露者预防严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染的暴露后预防效果：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):475. doi: 10.1186/s13063-020-04446-4.
4
Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.在医院环境中评估羟氯喹化学预防 SARS-CoV2 感染在医护人员中的疗效和安全性的对照、双盲、随机试验：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):472. doi: 10.1186/s13063-020-04400-4.
5
Failure of hydroxychloroquine pre-exposure prophylaxis in COVID-19 infection? A case report.羟氯喹预处理预防新型冠状病毒肺炎感染失败？一例病例报告。
J Antimicrob Chemother. 2020 Sep 1;75(9):2706-2707. doi: 10.1093/jac/dkaa213.
6
Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19.医护人员与 SARS-CoV-2 在印度的感染：COVID-19 时期的病例对照研究。
Indian J Med Res. 2020 May;151(5):459-467. doi: 10.4103/ijmr.IJMR_2234_20.
7
A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19).氯喹和羟氯喹在冠状病毒病-19（COVID-19）中的预防作用的系统评价。
Int J Rheum Dis. 2020 May;23(5):613-619. doi: 10.1111/1756-185X.13842. Epub 2020 Apr 27.
8
ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.羟氯喹用于 COVID-19 传染病的化学预防（PROLIFIC）以预防一线医护人员感染 COVID-19：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jul 2;21(1):604. doi: 10.1186/s13063-020-04543-4.
9
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.羟氯喹在非人类灵长类动物中对抗 SARS-CoV-2 感染的应用。
Nature. 2020 Sep;585(7826):584-587. doi: 10.1038/s41586-020-2558-4. Epub 2020 Jul 22.
10
Hydroxychloroquine prophylaxis for COVID-19 contacts in India.印度针对新冠病毒病接触者的羟氯喹预防措施
Lancet Infect Dis. 2020 Oct;20(10):1118-1119. doi: 10.1016/S1473-3099(20)30313-3. Epub 2020 Apr 17.
引用本文的文献
1
Hydroxychloroquine for prophylaxis of COVID-19 in health workers: A randomized clinical trial.羟氯喹用于卫生工作者 COVID-19 的预防：一项随机临床试验。
PLoS One. 2022 Feb 9;17(2):e0261980. doi: 10.1371/journal.pone.0261980. eCollection 2022.
本文引用的文献
1
Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19.医护人员与 SARS-CoV-2 在印度的感染：COVID-19 时期的病例对照研究。
Indian J Med Res. 2020 May;151(5):459-467. doi: 10.4103/ijmr.IJMR_2234_20.
2
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.羟氯喹作为 COVID-19 暴露后预防的随机试验。
N Engl J Med. 2020 Aug 6;383(6):517-525. doi: 10.1056/NEJMoa2016638. Epub 2020 Jun 3.
3
RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.撤回：羟氯喹或氯喹联合或不联合大环内酯类药物治疗新型冠状病毒肺炎：一项多国注册分析
Lancet. 2020 May 22. doi: 10.1016/S0140-6736(20)31180-6.
4
Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.羟氯喹啉是氯喹毒性较低的衍生物，在体外可有效抑制严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染。
Cell Discov. 2020 Mar 18;6:16. doi: 10.1038/s41421-020-0156-0. eCollection 2020.
5
New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?氯喹抗冠状病毒的抗病毒作用的新见解：对 COVID-19 有何期待？
Int J Antimicrob Agents. 2020 May;55(5):105938. doi: 10.1016/j.ijantimicag.2020.105938. Epub 2020 Mar 12.
6
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).羟氯喹治疗严重急性呼吸综合征冠状病毒 2 （SARS-CoV-2）的体外抗病毒活性和优化剂量设计预测。
Clin Infect Dis. 2020 Jul 28;71(15):732-739. doi: 10.1093/cid/ciaa237.
7
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
8
The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review.奎宁和结构相关抗疟药物的致心律失常性心脏毒性：系统评价。
BMC Med. 2018 Nov 7;16(1):200. doi: 10.1186/s12916-018-1188-2.
Zotero 插件